SUPERNUS PHARMACEUTICALS, INC. SUPERNUS PHARMACEUTICALS, INC. STRONGLY ENCOURAGES YOU TO SEEK THE ADVICE OF YOUR OWN LEGAL AND FINANCIAL ADVISORS WITH RESPECT TO YOUR AWARD AND ITS TAX CONSEQUENCES. FORM OF NON-STATUTORY TIME- BASED STOCK OPTION AGREEMENTTime-Based Stock Option Agreement • February 27th, 2024 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This agreement (the “Agreement”) evidences a stock option granted by Supernus Pharmaceuticals, Inc. (the “Company”) to the undersigned (the “Optionee”), pursuant to and subject to the terms of the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (the “Plan”), which is incorporated herein by reference.
SUPERNUS PHARMACEUTICALS, INC. SUPERNUS PHARMACEUTICALS, INC. STRONGLY ENCOURAGES YOU TO SEEK THE ADVICE OF YOUR OWN LEGAL AND FINANCIAL ADVISORS WITH RESPECT TO YOUR AWARD AND ITS TAX CONSEQUENCES. FORM OF TIME-BASED INCENTIVE STOCK OPTION AGREEMENTBased Incentive Stock Option Agreement • February 27th, 2024 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This agreement (the “Agreement”) evidences a stock option granted by Supernus Pharmaceuticals. Inc. (the “Company”) to the undersigned (the “Optionee”), an employee of the Company or one of its subsidiaries, pursuant to and subject to the terms of the Supernus Pharmaceuticals. Inc. 2021 Equity Incentive Plan (the “Plan”), which is incorporated herein by reference.
SETTLEMENT AGREEMENT BY AND BETWEEN SUPERNUS PHARMACEUTICALS, INC. AND APOTEX INC. APOTEX CORP. DATED AS OF JUNE 21, 2023License Agreement • February 27th, 2024 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS SETTLEMENT AGREEMENT, (this “Settlement Agreement”) is entered into as of June 21, 2023 (the “Effective Date”) by and between, Supernus Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, having offices located at 9715 Key West Avenue, Rockville, Maryland 20850, on behalf of itself and its Affiliates (“Supernus”), on the one hand, and Apotex Inc., a corporation organized and existing under the laws of Canada having offices located at 150 Signet Drive, Toronto, ON M9L 1T9, Canada, on behalf of itself and its Affiliates (“Apotex Inc.”) and Apotex Corp., a corporation organized under the laws of Delaware having offices located at 2400 North Commerce Parkway, Suite 400, Weston, Florida 33326, on behalf of itself and its Affiliates (“Apotex Corp.” and together with Apotex Inc., “Apotex”), on the other hand. Supernus and Apotex are collectively referred to herein as the “Parties,” or each individually as a “Party.”
SUPERNUS PHARMACEUTICALS, INC. PERFORMANCE SHARE UNIT AWARD AGREEMENTPerformance Share Unit Award Agreement • February 27th, 2024 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Performance Share Unit Award Agreement (the “Agreement”) is made and entered into as of , (the “Grant Date”). This Agreement evidences a performance share unit Award granted by Supernus Pharmaceuticals, Inc. (the “Company”) to the undersigned (“Participant”) pursuant to and subject to the terms of the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (the “Plan”), which is incorporated herein by reference. To the extent this Agreement evidences an Award with more than one tranche, each tranche has been assigned a Performance Period (as defined below) during which time the unique Performance Goal (as defined in Exhibit A attached hereto) can be achieved. Each tranche and the applicable Performance Period and Performance Goal are set forth in Exhibit A hereto. As set forth more fully below, the vesting of performance share units (“PSUs”) under each Award tranche is conditioned on, among other things, the Administrator’s review and certification in writing of the timely achie
FORM OF EXECUTIVE RETENTION AGREEMENTForm of Executive Retention Agreement • February 27th, 2024 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Maryland
THIS EXECUTIVE RETENTION AGREEMENT (this “Agreement”) is made and entered into this [·] day of [·], [·] (the “Effective Date”) by and between Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [·] (the “Executive”).
SUPERNUS PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • February 27th, 2024 • Supernus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Restricted Stock Unit Agreement (this “Agreement”) is made and entered into as of the date set forth below (the “Grant Date”) by and between SUPERNUS PHARMACEUTICALS, INC. (the “Company”) and the Employee (the “Participant”) who has signed or electronically accepted this Agreement in the manner specified in the Participant’s online account with the designated third-party plan administrator (“Third-Party Administrator”), pursuant to and subject to the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan (the “Plan”), which is incorporated herein by reference. Capitalized terms not explicitly defined in this Agreement shall have the meaning set forth in the Plan.
